Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

Published:2010-04-08 Issue:5 Volume:24 Page:1094-1096
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kosmider O,Gelsi-Boyer V,Slama L,Dreyfus F,Beyne-Rauzy O,Quesnel B,Hunault-Berger M,Slama B,Vey N,Lacombe C,Solary E,Birnbaum D,Bernard O A,Fontenay M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201052.pdf

Reference8 articles.

1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–773.

2. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.

3. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W et al. Distinct clinical and biological characteristics in adult acute myeloid leukemia bearing isocitrate dehydrogenase 1 (IDH1) mutation. Blood 2010. e-pub ahead of print 22 January 2010; doi: 10.1182/blood-2009-11-253070.

4. Schnittger S, Haferlach C, Ulke M, Kaya L, Weiss T, Kern W et al. IDH1 mutations are detected in 9.3% of all AML and are strongly associated with intermediate risk karyotype and unfavourable prognosis: a study of 999 patients. Blood 2009; 114 (abstract LBA-3).

5. Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 2004; 279: 33946–33957.

Cited by 217 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How we diagnose Myelodysplastic syndromes;Frontiers in Oncology;2024-09-13

2. DNA methylation in human diseases;Heliyon;2024-06

3. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms;Current Oncology;2024-04-23

4. Traitement des syndromes myélodysplasiques de haut risque;Bulletin du Cancer;2023-11

5. Research progress on the pathogenesis of the SDHB mutation and related diseases;Biomedicine & Pharmacotherapy;2023-11